Antipsychotics in MDD Augmentation

CME

Recent Evidence for Treatment Augmentation With Second-Generation Antipsychotics in Major Depressive Disorder

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: May 07, 2020

Expiration: May 06, 2021

Rakesh Jain
Rakesh Jain, MD, MPH

Activity

Progress
1
Course Completed

References

  1. Saltiel PH, Silvershein DI. Major depressive disorder: mechanism-based prescribing for personalized medicine. Neuropsychiatr Dis Treat. 2015;11:875-888.
  2. McIntyre RS, Fallu A, Konarski JZ. Measurable outcomes in psychiatric disorders: remission as a marker of wellness. Clin Ther. 2006;28:1882.
  3. Fava M. New approaches to the treatment of refractory depression. J Clin Psychiatry. 2000;61(suppl 1):26-32.
  4. Rush JA, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905-1917.
  5. Russell JM, Hawkins K, Ozminkowski RJ, et al. The cost consequences of treatment-resistant depression. J Clin Psychiatry. 2004;65:341-347.
  6. McIntyre RS, Suppes T, Tandon R, et al. Florida Best Practice Psychotherapeutic Medication Guidelines for Adults With Major Depressive Disorder. J Clin Psychiatry 2017;78:703-713.
  7. Aripiprazole package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2014.
  8. Olanzapine/fluoxetine package insert. Indianapolis, IN: Eli Lilly USA; 2019.
  9. Quetiapine XR package insert. Wilmington, DE: AstraZeneca; 2009.
  10. Brexpiprazole package insert. Tokyo, Japan: Otsuka; 2015.
  11. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. 2020. Available at: https://www.psychiatry.org/psychiatrists/practice/clinical-practice-guidelines. Accessed April 27, 2020.
  12. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166:980-991.
  13. Zhou X, Keitner GI, Qin B, et al. Atypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysis. Int J Neuropsychopharmacol. 2015;18:pyv060.
  14. Wang HR, Woo YS, Ahn HS, et al. Can atypical antipsychotic augmentation reduce subsequent treatment failure more effectively among depressed patients with a higher degree of treatment resistance? A meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2015;18:pyv023.
  15. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905-1917.
  16. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68:843-853.
  17. Tohen M, Case M, Trivedi MH, et al. Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J Clin Psychiatry. 2010;71:451-462.
  18. El-Khalili N, Joyce M, Atkinson S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2010;13:917-932.
  19. Thase ME, Youakim JM, Skuban A, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015;76:1224-1231.
  20. DiBonaventura M, Gabriel S, Dupclay L, et al. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry. 2012;12:20.
  21. Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7:64-77.
  22. Taylor J, Stubbs B, Hewitt C, et al. The effectiveness of pharmacological and non-pharmacological interventions for improving glycaemic control in adults with severe mental illness: a systematic review and meta-analysis. PLoS One. 2017;12:e0168549.
  23. Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology. 2010;35:1520-1530.
  24. Correll CU. Balancing efficacy and safety in treatment with antipsychotics. CNS Spectr. 2007;12:12-20.
  25. Salem H, Nagpal C, Pigott T, et al. Revisiting antipsychotic-induced akathisia: current issues and prospective challenges. Current Neuropharmacol. 2017;15:789-798.
  26. Kristensen E. Sexual side effects induced by psychotropic drugs. Dan Med Bull. 2002;49:349-352.
  27. Clayton AH, Alkis AR, Parikh NB, et al. Sexual dysfunction due to psychotropic medications. Psychiatr Clin North Am. 2016;39:427-463.
  28. Halbreich U, Kinon BJ, Gilmore JA, et al. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology. 2003;28:53-67.
  29. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951-962.
  30. Ivkovic J, Lindsten A, George V, et al. Effect of brexpiprazole on prolactin an analysis of short- and long-term studies in schizophrenia. J Clin Psychopharmacol. 2019;39:13-19.
  31. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. Available at: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf. Accessed April 27, 2020.